Researcher

Daichi Watanabe

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · JOURNAL ARTICLE

Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab

Journal of Gastrointestinal Cancer

Retrospective cohort study identifying mGPS 2 as a time-dependent predictor of overall survival in advanced gastric cancer, but with modest sample size, observational design, and no practice-changing effect size or mechanistic clarity.

PromisingHironori Fujii Daichi Watanabe Akio Suzuki

Reported

Overall survival, time-dependent…HR 2.17 (95% CI 1.15–4.10)

Overall survival p-value0.017

Progression-free survival, time-d…HR 1.49 (95% CI 0.69–3.20)

AUG 15, 2026 · JOURNAL ARTICLE

Global inequitable distribution of seminal studies of chemotherapy-induced nausea and vomiting

Supportive Care in Cancer

A descriptive analysis of published trial citations in three major guidelines, identifying a geographic and economic disparity in the evidence base for CINV antiemetics, but without direct clinical outcome data or intervention testing.

PreliminaryGaoshang Chai Hirotoshi Iihara Jennifer Leigh

Reported

High-income country origin82.7%

Low- and middle-income country or…17.3%

Highly emetogenic chemotherapy st…63.1%